More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
Understanding patents & medicine access the WTO, free trade agreements & patent law.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Thailand’s fight for national sovereignty - the issue of compulsory licenses Since coup Sept 2006, the new interim government issued compulsory licenses.
UNITAID Innovative Financing Mechanism  Denis Broun Executive Director.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
 Broad-based health care company that discovers, develops, manufactures, and markets products and services  Abbott's main businesses: ◦ Global pharmaceuticals.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
The Global Pharmaceutical Industry Timothy F Christian, MD, MPA.
The use of TRIPS flexibilities to protect health in South Africa and the opportunities for pro-public health reform of national legislation Nokhwezi Hoboyi.
Presentation to Civil Society meeting Lusaka 1 October 2013.
Presentation to Civil Society meeting Maseru 12 August 2014.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.
NON COMMUNICABLE DISEASE What is a noncommunicable disease?
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,
A very short introduction to patents & access to medicines.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.
Hong Kong Agreement on IPR and Access to Medicines: Public Health & Human Rights Considerations J. Craig Phillips LLM, MSN, ARNP, BC, ACRN Florida International.
1 Who will innovate to meet the health needs of low income populations in developing countries? Joanna Chataway ESRC INNOGEN Centre Dinar Kale ESRC INNOGEN.
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Colin McInnes Simon Rushton Owain Williams. From NHS to ‘Global Health’
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
 .
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.
1 MIAG 2 Response to Industry -Emerging markets Eva M A Ombaka.
TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.
Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.
Global Patent Debate K.Ravi Srinivas May 12-13, 2011.
 The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.  Pharmaceutical companies are.
Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Coach Robinson Health Class Notes and Information.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
Presentation to Civil Society meeting Harare 21 January 2014.
Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Ellen ‘t Hoen Médecins sans Frontières
PRIORITIZING HEALTH IN U.S. TRADE POLICY: A CASE EXAMPLE.
Unit 5 and 6 Professor Smith. Unit 5 Assignments Read Chapter 6 in the course textbook Read the supplemental readings for this unit Participate in the.
Access to Medications: An introduction Braveen Ragunanthan Keanan McGonigle Slides prepared by: Alison Case, Education and Advocacy Fellow Katrina Ciraldo,
Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.
A Market for Vaccines Xavier Sala-i-Martin Columbia University November 2005.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
CAFTA: Boon to Innovation, or Obstacle for Women? Ellen R. Shaffer PhD MPH, Joe Brenner MA Center for Policy Analysis on Trade and Health (CPATH)
AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.
BRIC Health Systems and Big Pharma: Strategic Policy Issues
Topic and Country Assignments
Topic and Country Assignments
Intellectual Property Protection and Access to Medicines
Policy Options for Low and Middle Income Countries (LMIC)
An Increasing Demand for Prescription Drugs Drives Profitability
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

More on Generic Drugs Global Classrooms 2013 Rachel Hunkler

Non-communicable diseases Also known as “chronic diseases” They are not contagious! – Ex: cancer, diabetes, Alzheimer's, MS, arthritis, heart disease “…non-communicable disease…accounts for more than 60 percent of deaths globally (80% in the developing world)” 1 Big Pharma relies on profits from the sales of medicines for these diseases Big Pharma says nations abuse the rights to issue compulsory licenses – Especially middle-income nations with non- communicable diseases! 1 Global Classrooms,. Global Classrooms. World Health Organization (WHO). Print.

Out of 57 million global deaths in 2008, 36 million (63%) were due to non-communicable diseases. Do you think this is a problem that the UN needs to tackle?? Many developed nations have strict patent protection laws. They say that diseases such as cancer and diabetes are less than an emergency than HIV/AIDs, malaria, and TB. What do you think?? Stop and think…

Generic Drug Market 79% of the world market relies on generic drugs 80% of all generic AVRs (drugs to fight HIV/AIDs) are made in India! Top generic drug companies: – Ratiopharm (Germany) – Teva Pharmaceutical Industries (Israel) – Ranbaxy (India) In 2012, many AVR patents expired and many more will expire in What does this mean for Big Pharma??

“Tiered Pricing” CountryGPD per capita (in USD) Brand-Name Drug Price USA$47, 882$100 Argentina$10, 994$65 Somalia$907$20 Tiered Pricing allows developing nations to buy directly from Big Pharma companies at lower prices. Tiered Pricing reduces the need for compulsory licenses. How does this affect low-income countries (undeveloped)?? How does this affect middle-income countries (developing)??

“Patent Pooling” UNITAID = UN initiative dealing with the purchase of medical drugs Clinton Foundation + UNITAID = “Medical Patent Pool” program Medical Patent Pool Generic Drug for HIV/AIDs Generic Drug for Malaria Generic Drug for TB

Recent International Agreements TRIPS Agreement in 1994 – 20-year patent period became the law – Compulsory patent licenses can be issued in times of severe emergencies Doha Declaration in 2011 – If one nation issues a compulsory license, other nations can simply buy the drugs from that nation

Up for Debate… Is it fundamentally unfair for generic drugs to be produced at all? Is it right that smaller companies can make money of the R&D of large pharmaceutical companies? Does the fact that it makes lifesaving drugs more accessible make a difference? Since lifesaving drugs are generally inaccessible to the world’s poor during the patent period, critics charge that major drug companies are simply profiting at the expense of the lives of the world’s poor. Given that patents make drugs less accessible, is it right to patent them at all? Global Classrooms,. Global Classrooms. World Health Organization (WHO). Print.